Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Leishmaniasis chemotherapy--challenges and opportunities.

Croft SL, Olliaro P.

Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x. Review.

PMID:
21933306
[PubMed - indexed for MEDLINE]
2.

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.

Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK, Das P.

J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.

PMID:
22278840
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.

Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.

PMID:
22882665
[PubMed - indexed for MEDLINE]
Free Article
4.

Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.

Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.

J Assoc Physicians India. 2003 Jul;51:686-90. Review.

PMID:
14621038
[PubMed - indexed for MEDLINE]
5.

Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.

Ramos A, Cruz I, Muñez E, Salas C, Fernández A, Alvarez-Espejo T.

Infection. 2008 Mar;36(2):184-6. doi: 10.1007/s15010-007-6279-5. Epub 2008 Mar 10. No abstract available.

PMID:
18327683
[PubMed - indexed for MEDLINE]
6.

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.

PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.

PMID:
22629478
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.

Das VN, Pandey K, Singh D, Forwood C, Lal CS, Das P.

J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.

PMID:
24029204
[PubMed - indexed for MEDLINE]
Free Article
8.

Treatment of leishmaniasis with miltefosine: 2008 status.

Berman JJ.

Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209. Review.

PMID:
18721114
[PubMed - indexed for MEDLINE]
9.

Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Mishra J, Madhubala R, Singh S.

Parasitol Res. 2013 Mar;112(3):1001-9. doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18.

PMID:
23242321
[PubMed - indexed for MEDLINE]
10.

Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.

Rihl M, Stoll M, Ulbricht K, Bange FC, Schmidt RE.

J Infect. 2006 Jul;53(1):e25-7. Epub 2005 Nov 7.

PMID:
16274744
[PubMed - indexed for MEDLINE]
11.

Current scenario of drug development for leishmaniasis.

Croft SL, Seifert K, Yardley V.

Indian J Med Res. 2006 Mar;123(3):399-410. Review.

PMID:
16778319
[PubMed - indexed for MEDLINE]
12.

Injectable paromomycin for Visceral leishmaniasis in India.

Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.

N Engl J Med. 2007 Jun 21;356(25):2571-81.

PMID:
17582067
[PubMed - indexed for MEDLINE]
Free Article
13.

Leishmaniasis: an update of current pharmacotherapy.

Sundar S, Chakravarty J.

Expert Opin Pharmacother. 2013 Jan;14(1):53-63. doi: 10.1517/14656566.2013.755515. Epub 2012 Dec 21. Review.

PMID:
23256501
[PubMed - indexed for MEDLINE]
14.
15.

Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.

Am J Trop Med Hyg. 2009 Mar;80(3):336-8.

PMID:
19270277
[PubMed - indexed for MEDLINE]
Free Article
16.

Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.

Singh S, Kumar J, Singh R, Dwivedi SN.

Int J Infect Dis. 2000;4(4):203-8.

PMID:
11231183
[PubMed - indexed for MEDLINE]
17.

Chemotherapy of leishmaniasis.

Croft SL, Yardley V.

Curr Pharm Des. 2002;8(4):319-42. Review.

PMID:
11860369
[PubMed - indexed for MEDLINE]
18.

Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India.

Das VN, Ranjan A, Pandey K, Singh D, Verma N, Das S, Lal CS, Sinha NK, Verma RB, Siddiqui NA, Das P.

Am J Trop Med Hyg. 2012 Jun;86(6):959-61. doi: 10.4269/ajtmh.2012.11-0467.

PMID:
22665600
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Leishmaniasis: new insights from an old and neglected disease.

Antinori S, Schifanella L, Corbellino M.

Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):109-18. doi: 10.1007/s10096-011-1276-0. Epub 2011 May 1. Review.

PMID:
21533874
[PubMed - indexed for MEDLINE]
20.

Cutaneous leishmaniasis treatment.

Minodier P, Parola P.

Travel Med Infect Dis. 2007 May;5(3):150-8. Epub 2006 Oct 31. Review.

PMID:
17448941
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk